Company Filing History:
Years Active: 2021-2023
Title: Innovations by Marion Blomenrohr
Introduction
Marion Blomenrohr is an accomplished inventor based in Nijmegen, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for cancer treatment. With a total of 2 patents, his work focuses on innovative solutions for targeting specific cancer antigens.
Latest Patents
Blomenrohr's latest patents include groundbreaking inventions related to Anti-5T4 antibodies and antibody-drug conjugates. The first patent describes antibodies against the human 5T4 oncofoetal antigen, which are suitable for clinical trials. These antibodies are cross-reactive for humans and cynomolgus monkeys, exhibiting a strong affinity for the human 5T4 antigen. The second patent further elaborates on CDR defined antibodies targeting the 5T4 oncofoetal antigen, emphasizing their potential in treating solid tumors and hematological malignancies.
Career Highlights
Marion Blomenrohr is currently associated with Byondis B.V., a company dedicated to advancing cancer therapies. His work at Byondis has positioned him as a key player in the development of innovative antibody-based treatments. His research has the potential to significantly impact the landscape of cancer therapy.
Collaborations
Blomenrohr collaborates with notable colleagues, including Miranda Maria Cornelia Van Der Lee and Gerardus Joseph Andreas Ariaans. These collaborations enhance the research and development efforts at Byondis, fostering an environment of innovation and discovery.
Conclusion
Marion Blomenrohr's contributions to the field of biotechnology through his patents and collaborations highlight his commitment to advancing cancer treatment. His work continues to pave the way for innovative therapies that could improve patient outcomes.